Minnesota Administrative Rules
Agency 144 - Health Department
Chapter 4605 - COMMUNICABLE DISEASES
REPORTING REQUIREMENTS
Part 4605.7040 - DISEASE AND REPORTS; CLINICAL MATERIALS SUBMISSIONS
Universal Citation: MN Rules 4605.7040
Current through Register Vol. 49, No. 13, September 23, 2024
Persons required to report under this chapter shall report to the commissioner cases, suspected cases, carriers, and deaths due to the following diseases and infectious agents. When submission of clinical materials is required under this part, submissions shall be made to the Minnesota Department of Health, Public Health Laboratory.
A. Diseases reportable immediately by telephone to the commissioner:
(1) anthrax
(Bacillus anthracis). Submit clinical materials;
(2) botulism (Clostridium
botulinum);
(3)
brucellosis (Brucella abortus, Brucella canis, Brucella melitensis,
Brucella suis). Submit clinical materials;
(4) cholera (Vibrio
cholerae). Submit clinical materials;
(5) diphtheria (Corynebacterium
diphtheriae). Submit clinical materials;
(6) free-living amebic infection (including
at least: Acanthamoeba spp., Naegleria fowleri,
Balamuthia spp., Sappinia spp). Submit clinical
materials;
(7) glanders
(Burkholderia mallei). Submit clinical materials;
(8) hemolytic uremic syndrome. Submit
clinical materials;
(9) measles
(rubeola). Submit clinical materials;
(10) melioidosis (Burkholderia
pseudomallei). Submit clinical materials;
(11) meningococcal disease (Neisseria
meningitidis) (all invasive disease). Submit clinical
materials;
(12) Middle East
Respiratory Syndrome (MERS). Submit clinical materials;
(13) orthopox virus. Submit clinical
materials;
(14) plague
(Yersinia pestis). Submit clinical materials;
(15) poliomyelitis. Submit clinical
materials;
(16) Q fever
(Coxiella burnetii). Submit clinical materials;
(17) rabies (animal and human cases and
suspected cases);
(18) rubella and
congenital rubella syndrome. Submit clinical materials;
(19) severe acute respiratory syndrome
(SARS). Submit clinical materials;
(20) smallpox (variola). Submit clinical
materials;
(21) tularemia
(Francisella tularensis). Submit clinical materials;
and
(22) viral hemorrhagic fever
(including but not limited to Ebola virus disease and Lassa fever). Submit
clinical materials.
B. Diseases reportable within one working day:
(1) anaplasmosis (Anaplasma
phagocytophilum)
(2)
arboviral disease, including, but not limited to, La Crosse encephalitis,
Eastern equine encephalitis, Western equine encephalitis, St. Louis
encephalitis, West Nile virus disease, Powassan virus disease, and Jamestown
Canyon virus disease;
(3) babesiosis
(Babesia spp.);
(4) blastomycosis (Blastomyces
dermatitidis or B. gilchristii);
(5) bluegreen algae
(Cyanobacteria) and cyanotoxin poisoning;
(6) campylobacteriosis
(Campylobacter spp.). Submit clinical materials;
(7)
Candida auris
(C. auris). Submit clinical materials;
(8)
Capnocytophaga
canimorsus;
(9)
carbapenem-resistant Acinetobacter baumannii (CRAB). Submit
clinical materials;
(10)
carbapenem-resistant Enterobacterales (CRE). Submit clinical
materials;
(11)
carbapenemase-producing carbapenem-resistant Pseudomonas
aeruginosa (CP-CRPA). Submit clinical materials;
(12) cat scratch disease (infection caused by
Bartonella species);
(13) chancroid (Haemophilus
ducreyi);
(14) chikungunya
disease;
(15)
Chlamydia
trachomatis infections, (including serotypes L1, L2, and
L3);
(16)
coccidioidomycosis;
(17)
cytomegalovirus (congenital - positive laboratory results collected from
infants less than or equal to 90 days of age, or from amniotic
fluid);
(18)
Cronobacter
sakazakii in infants under one year of age. Submit clinical materials;
(19) cryptosporidiosis
(Cryptosporidium spp.). Submit clinical materials;
(20) cyclosporiasis
(Cyclospora spp.). Submit clinical materials;
(21) dengue virus infection;
(22) ehrlichiosis (Ehrlichia
spp.);
(23) encephalitis (caused by
viral agents);
(24) enteric
Escherichia coli infection (E. coli O157:H7,
other Shiga toxin-producing (enterohemorrhagic) E. coli,
enteropathogenic E. coli, enteroinvasive E.
coli, enteroaggregative E. coli, enterotoxigenic
E. coli, or other pathogenic E. coli). Submit
clinical materials;
(25) giardiasis
(Giardia duodenalis);
(26) gonorrhea (Neisseria
gonorrhoeae infections). Submit clinical materials isolated from a
normally sterile site and upon request;
(27)
Haemophilus influenzae
disease (all invasive disease). Submit clinical materials;
(28) hantavirus infection;
(29) hard tick relapsing fever
(Borrelia miyamotoi);
(30) hepatitis (all primary viral types
including A, B, C, D, and E). Submit clinical materials for hepatitis A upon
request;
(31) histoplasmosis
(Histoplasma capsulatum);
(32) human immunodeficiency virus (HIV) infection, including
acquired immunodeficiency syndrome (AIDS);
(33) influenza (unusual case incidence,
critical illness, or laboratory confirmed cases). Submit clinical
materials;
(34) Kawasaki
disease;
(35)
Kingella spp. (invasive only). Submit clinical
materials;
(36) legionellosis
(Legionella spp.). Submit clinical materials;
(37) leprosy (Hansen's disease)
(Mycobacterium leprae);
(38) leptospirosis (Leptospira
interrogans);
(39)
listeriosis (Listeria monocytogenes). Submit clinical
materials;
(40) Lyme disease
(Borrelia burgdorferi and other Borrelia
spp.);
(41) malaria
(Plasmodium spp.);
(42) meningitis (caused by viral
agents);
(43) multisystem
inflammatory syndrome associated with SARS-CoV-2 infection, including in
children (MIS-C) and adults (MIS-A);
(44) mumps. Submit clinical
materials;
(45) neonatal sepsis
(bacteria isolated from a sterile site, excluding coagulase-negative
Staphylococcus) less than seven days after birth. Submit
clinical materials;
(46) pertussis
(Bordetella pertussis). Submit clinical materials;
(47) psittacosis (Chlamydophila
psittaci);
(48) rat-bite
fever (Streptobacillus moniliformis);
(49) salmonellosis, including typhoid
(Salmonella spp.). Submit clinical materials;
(50) SARS-CoV-2 infection (CQVID-19) (unusual
case incidence, critical illness, or laboratory confirmed cases). Submit
clinical materials;
(51) shigellosis
(Shigella spp.). Submit clinical materials;
(52) Spotted fever rickettsiosis
(Rickettsia spp. infections, including Rocky Mountain spotted
fever);
(53)
Staphylococcus
aureus (only vancomycin-intermediate Staphylococcus
aureus (VISA), vancomycin-resistant Staphylococcus
aureus (VRSA), and death or critical illness due to
community-associated Staphylococcus aureus in a previously
healthy individual). Submit clinical materials;
(54) streptococcal disease (all invasive
disease caused by Groups A and B streptococci and S.
pneumoniae [including urine antigen laboratory-confirmed pneumonia]).
Except for urine, submit clinical materials;
(55) syphilis (Treponema
pallidum);
(56) tetanus
(Clostridium tetani);
(57) toxic shock syndrome. Submit clinical
materials;
(58) toxoplasmosis
(Toxoplasma gondii);
(59) transmissible spongiform
encephalopathy;
(60) trichinosis
(Trichinella spiralis);
(61) tuberculosis (Mycobacterium
tuberculosis complex) (pulmonary or extrapulmonary sites of disease,
including clinically diagnosed disease). Latent tuberculosis infection is not
reportable. Submit clinical materials;
(62) typhus (Rickettsia
spp.);
(63) varicella (chickenpox).
Submit clinical materials;
(64)
Vibrio spp. Submit clinical materials;
(65) yellow fever;
(66) yersiniosis, enteric
(Yersinia spp.). Submit clinical materials;
(67) zika virus disease; and
(68) zoster (shingles) (all cases <18
years old; other unusual case incidence or complications regardless of age).
Submit clinical materials.
Statutory Authority: MS s 144.05; 144.072; 144.0742; 144.12; 144.122
Disclaimer: These regulations may not be the most recent version. Minnesota may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.